Psychopharmacological treatment of schizophrenia: What do we have, and what could we get?

Neuropharmacology

Volumn 62, Issue 3, 2012, Pages 1371-1380

  Ellenbroek, Bart A ^a  

^a VICTORIA UNIVERSITY OF WELLINGTON   (New Zealand)

Author keywords

5 HT6 receptors, H3 receptors; Antipsychotic drugs; Clinical trials; Dopamine; Glutamate; Glycine transporters; Metabotropic glutamate receptors; PDE10; Schizophrenia; Serotonin

Indexed keywords

1,2,3,4,8,9,10,10A OCTAHYDRO 7BH CYCLOPENTA[B][1,4]DIAZEPINO[6,7,1 HI]INDOLE; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; AMISULPRIDE; ARIPIPRAZOLE; BIFEPRUNOX; BUSPIRONE; CARIPRAZINE; CLOZAPINE; CP 809101; DOPAMINE 2 RECEPTOR; FARAMPATOR; HALOPERIDOL; HISTAMINE H1 RECEPTOR ANTAGONIST; LURASIDONE; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RG 1678; RISPERIDONE; SEROTONIN 2 ANTAGONIST; SEROTONIN 2A ANTAGONIST; SEROTONIN 2C AGONIST; SEROTONIN 2C ANTAGONIST; SERTINDOLE; TANDOSPIRONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VABICASERIN; ZIPRASIDONE; ZOTEPINE;

BINDING AFFINITY; BINDING SITE; BRAIN REGION; CLINICAL FEATURE; DEPRESSION; DISEASE ASSOCIATION; DOSE RESPONSE; DROWSINESS; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TARGETING; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MOLECULAR PATHOLOGY; NONHUMAN; ORTHOSTATIC HYPOTENSION; PREDICTION; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PSYCHOPHARMACOLOGY; REVIEW; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SIDE EFFECT; UNCERTAINTY; WEIGHT GAIN;

ANIMALS; ANTIPSYCHOTIC AGENTS; DOPAMINE AGENTS; DRUG DISCOVERY; EXCITATORY AMINO ACID AGENTS; HUMANS; PSYCHOPHARMACOLOGY; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 84856080078     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2011.03.013     Document Type: Review

References (125)

1. A. Abi-Dargham, J. Rodenhiser, D. Printz, P.Y. Zea, R. Gil, L.S. Kegeles, R. Weiss, T.B. Cooper, J.J. Mann, H.R.L. Van, J.M. Gorman, and M. Laruelle Increased baseline occupancy of D-2 receptors by dopamine in schizophrenia Proceedings of the National Academy of Sciences of the United States of America 97 2000 8104 8109 (Pubitemid 30460780)
2. M. Agius, A. Davis, M. Gilhooley, S. Chapman, and R. Zaman What do large scale studies of medication in schizophrenia add to our management strategies? Psychiatria Danubina 22 2010 323 328
3. J. Angst, D. Bente, P. Berner, H. Helmann, H. Helmchen, and H. Hippius Das klinische Wirkungsbild von Clozapin Pharmacopsychiatry 4 1971 201 211
4. F.J. Ayd Jr. A survey of drug-induced extrapyramidal reactions Journal of American Medical Association 175 1961 1054 1060
5. A.T. Bender, and J.A. Beavo Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use Pharmacological Reviews 58 2006 488 520 (Pubitemid 44394910)
6. J.A. den Boer, and J. Korf Dopamine receptor subtypes and schizophrenia: a clinical perspective B.A. Ellenbroek, A.R. Cools, Atypical Antipsychotics 2000 Birkhäuser Verlag Basel 163 190
7. G. Bongers, R.A. Bakker, and R. Leurs Molecular aspects of the histamine H-3 receptor Biochemical Pharmacology 73 2007 1195 1204 (Pubitemid 46413181)
8. C.L.E. Broekkamp, S.K. Oosterloo, H.H.G. Berendsen, and A.M.L. Van Delft Effect of metergoline, fenfluramine, and 8-OHDPAT on catalepsy induced by haloperidol or morphine Naunyn-Schmiedeberg's Archives of Pharmacology 338 1988 191 195
9. N. Brunello, C. Masotto, L. Steardo, R. Markstein, and G. Racagni New insights into the biology of schizophrenia through the mechanism of action of clozapine Neuropsychopharmacology 13 1995 177 213
10. S. Bullich, M. Slifstein, J. Passchier, N.V. Murthy, L.S. Kegeles, J.H. Kim, X. Xu, R.N. Gunn, R. Herance, J.D. Gispert, A. Gutiérrez, M. Farré, M. Laruelle, and A.M. Catafau Biodistribution and radiation dosimetry of the glycine transporter-1 ligand 11C-GSK931145 determined from primate and human whole-body PET Molecular Imaging and Biology 2010 1 9
11. J. Cartmell, K.W. Perry, C.R. Salhoff, J.A. Monn, and D.D. Schoepp Acute increases in monoamine release in the rat prefrontal cortex by the mGlu2/3 agonist LY379268 are similar in profile to risperidone, not locally mediated, and can be elicited in the presence of uptake blockade Neuropharmacology 40 2001 847 855 (Pubitemid 32510798)
12. E.S. Choe, E.H. Shin, and J.Q. Wang Regulation of phosphorylation of NMDA receptor NR1 subunits in the rat neostriatum by group I metabotropic glutamate receptors in vivo Neuroscience Letters 394 2006 246 251 (Pubitemid 43144859)
13. J. Cole, and D. Clyde Extrapyramidal side effects and clinical response to the phenothazines Revue Canadienne de Biologie 20 1961 565 574
14. P.H. Connell Amphetamine Psychosis 1958 Oxford University Press London
15. T.M. Coskran, D. Morton, F.S. Menniti, W.O. Adamowicz, R.J. Kleiman, A.M. Ryan, C.A. Strick, C.J. Schmidt, and D.T. Stephenson Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species Journal of Histochemistry and Cytochemistry 54 2006 1205 1213 (Pubitemid 44623341)
16. N.A. Crossley, M. Constante, P. McGuire, and P. Power Efficacy of atypical v. typical antipsychotics in the treatment of early psychosis: meta-analysis British Journal of Psychiatry 196 2010 434 439
17. J.M. Davis, N. Chen, and I.D. Glick A meta-analysis of the efficacy of second-generation antipsychotics Archives of General Psychiatry 60 2003 553 564 (Pubitemid 36682312)
18. N.M.W.J. De Bruin, E.L.J.M. Van Luijtelaar, A.R. Cools, and B.A. Ellenbroek Filtering disturbances in schizophrenic patients. gating of auditory evoked potentials and prepulse inhibition of the acoustic startle response compared. Emphasis on the role of dopamine Current Neuropharmacology 1 2003 51
19. G. Di Giovanni, V. Di Matteo, M. Di Mascio, and E. Esposito Preferential modulation of mesolimbic vs. nigrostriatal dopaminergic function by serotonin(20C/2B) receptor agonists: a combined in vivo electrophysiological and microdialysis study Synapse 35 2000 53 61
20. B.A. Ellenbroek Treatment of schizophrenia: a clinical and preclinical evaluation of neuroleptic drugs Pharmacology and Therapeutics 57 1993 1 78 (Pubitemid 23130739)
21. B.A. Ellenbroek Animal models in the genomic era: possibilities and limitations with special emphasis on schizophrenia Behavioural Pharmacology 14 2003 409 417 (Pubitemid 37176799)
22. B.A. Ellenbroek Schizophrenia G.F. Koob, M. Le Moal, R.F. Thompson, Encyclopedia of Behavioral Neuroscience 2010 Academic Press Oxford 188 195
23. B.A. Ellenbroek, E.P. Prinssen, and A.R. Cools The role of serotonin receptor subtypes in the behavioural effects of neuroleptic drugs. A paw test study in rats European Journal of Neuroscience 6 1994 1 8 (Pubitemid 24022660)
24. B.A. Ellenbroek, F. Sams Dodd, and A.R. Cools Simulation models for schizophrenia B.A. Ellenbroek, A.R. Cools, Atypical Antipsychotics 2000 Birkhauser Verlag Basel 121 142
25. B.A. Ellenbroek, X.X. Zhang, and G.Z. Jin Effects of (-)stepholidine in animal models for schizophrenia Acta Pharmacologica Sinica 27 2006 1111 1118 (Pubitemid 44410990)
26. E.S. Emamian, M. Karayiorgou, and J.A. Gogos Decreased phosphorylation of NMDA receptor type 1 at serine 897 in brains of patients with schizophrenia Journal of Neuroscience 24 2004 1561 1564 (Pubitemid 38240950)
27. R.W. Feenstra, J. de Moes, J.J. Hofma, H. Kling, W. Kuipers, S.K. Long, M.T.M. Tulp, J.A.M. van der Heyden, and C.G. Kruse New 1-aryl-4- (biarylmethylene)piperazines as potential atypical antipsychotics sharing dopamine D2-receptor and serotonin 5-HT1A-receptor affinities Bioorganic & Medicinal Chemistry Letters 11 2001 2345 2349 (Pubitemid 32781696)
28. M.J. Fell, K.A. Svensson, B.G. Johnson, and D.D. Schoepp Evidence for the role of metabotropic glutamate (mGlu)2 Not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4- amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039) Journal of Pharmacology and Experimental Therapeutics 326 2008 209 217 (Pubitemid 351872145)
29. G.B. Fox, J.B. Pan, R.J. Radek, A.M. Lewis, R.S. Bitner, T.A. Esbenshade, R. Faghih, Y.L. Bennani, M. Williams, B.B. Yao, M.W. Decker, and A.A. Hancock Two novel and selective nonimidazole H3 receptor antagonists A-304121 and A-317920: in vivo behaviral and neurophysiological characterization Journal of Pharmacology and Experimental Therapeutics 305 2003 897 903
30. R. Freedman, M. Hall, L.E. Adler, and S. Leonard Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia Biological Psychiatry 38 1995 22 33
31. R. Freedman, C.E. Adams, and S. Leonard The alpha 7-nicotinic acetylcholine receptor and the pathology of hippocampal interneurons in schizophrenia Journal of Chemical Neuroanatomy 20 2000 299 306 (Pubitemid 32162888)
32. R. Freedman, S. Leonard, J.M. Gault, J. Hopkins, C.R. Cloninger, C.A. Kaufmann, M.T. Tsuang, S.V. Farone, D. Malaspina, D.M. Svrakic, A. Sanders, and P. Gejman Linkage disequilibrium for schizophrenia at the chromosome 15q13-14 locus of the alpha 7-nicotinic acetylcholine receptor subunit gene (CHRNA7) American Journal of Medical Genetics 105 2001 22
33. R. Freedman, A. Olincy, R.W. Buchanan, J.G. Harris, J.M. Gold, L. Johnson, D. Allensworth, A. Guzman-Bonilla, B. Clement, M.P. Ball, J. Kutnick, V. Pender, L.F. Martin, K.E. Stevens, B.D. Wagner, G.O. Zerbe, F. Soti, and W.R. Kem Initial phase 2 trial of a nicotinic agonist in schizophrenia American Journal of Psychiatry 165 2008 1040 1047
34. R. Galici, N.G. Echemendia, A.L. Rodriguez, and P.J. Conn A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity Journal of Pharmacology and Experimental Therapeutics 315 2005 1181 1187 (Pubitemid 41635406)
35. M.J. Gemkow, A.J. Davenport, S. Harich, B.A. Ellenbroek, A. Cesura, and D. Hallett The histamine H3 receptor as a therapeutic drug target for CNS disorders Drug Discovery Today 14 2009 509 515
36. D.C. Goff, K.K. Midha, A.W. Brotman, S. McCormick, M. Waites, and E.T. Amico An open trial of buspirone added to neuroleptics in schizophrenic patients Journal of Clinical Psychopharmacology 11 1991 193 197
37. D.C. Goff, J.S. Lamberti, A.C. Leon, M.F. Green, A.L. Miller, J. Patel, T. Manschreck, O. Freudenreich, and S.A. Johnson A placebo-controlled add-on trial of the ampakine, CX516, for cognitive deficits in schizophrenia Neuropsychopharmacology 33 2008 465 472
38. R.G. Greenslade, and S.N. Mitchell Selective action of (-)-2-oxa-4-aminobicyclo[3.1.0] hexane-4,6-dicarboxylate (LY379268), a group II metabotropic glutamate receptor agonist, on basal and phencyclidine-induced dopamine release in the nucleus accumbens shell Neuropharmacology 47 2004 1 8 (Pubitemid 38686306)
39. K.J. Gregory, E.N. Dong, J. Meiler, and P.J. Conn Allosteric modulation of metabotropic glutamate receptors: structural insights and therapeutic potential Neuropharmacology 60 2011 66 81
40. F.E. Greifenstein, J. Yoshitake, M. DeValut, and J.E. Gajewski A study of l-aryl cyclohexyl amine for anesthesia Anesthesia & Analgesia 37 1958 283 294
41. G. Grunder Cariprazine, an orally active D2/D3 receptor antagonist, for the potential treatment of schizophrenia, bipolar mania and depression Current Opinions in Investigational Drugs 11 2010 10
42. G. Grunder, H. Hippius, and A. Carlsson The 'atypicality' of antipsychotics: a concept re-examined and re-defined Nature Reviews Drug Discovery 8 2009 6
43. H.J. Haase, M. Zahn, and C.F. Zschucke Influence of anti-neuroleptic action on the Neuroceptic threshold International Journal of Neuropsychiatry 1 1965 239 252
44. T.G. Hamill, W. Eng, A. Jennings, R. Lewis, S. Thomas, S. Wood, L. Street, D. Wisnoski, S. Wolkenberg, C. Lindsley, S.M. Sanabria-Bohórquez, S. Patel, K. Riffel, C. Ryan, J. Cook, C. Sur, H.D. Burns, and R. Hargreaves The synthesis and preclinical evaluation in rhesus monkey of [18F]MK-6577 and [11C]CMPyPB glycine transporter 1 p.sitron emission tomography radiotracers Synapse 65 2011 261 270
45. K. Hashimoto Glycine transport inhibitors for the treatment of schizophrenia Open Medicinal Chemistry Journal 4 2010 10 19
46. E. Herman, and H. Pleasure Clinical evaluation of thioridazine and chlorpromazine in chronic schizophrenics Diseases of the Nervous System 24 1963 6
47. H. Hippius The history of clozapine Psychopharmacology 99 1989 S3 S5
48. W.D. Hirst, B. Abrahamsen, F.E. Blaney, A.R. Calver, L. Aloj, G.W. Price, and A.D. Medhurst Differences in the central nervous system distribution and pharmacology of the mouse 5-hydroxytryptamine-6 receptor compared with rat and human receptors investigated by radioligand binding, site-directed mutagenesis, and molecular modeling Molecular Pharmacology 64 2003 1295 1308 (Pubitemid 37532219)
49. J. Ichikawa, H. Ishii, S. Bonaccorso, W.L. Fowler, I.A. O'Laughlin, and H.Y. Meltzer 5-HT2A and D-2 receptor blockade increases cortical DA release via 5-HT1A receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release Journal of Neurochemistry 76 2001 1521 1531 (Pubitemid 32198256)
50. J. Idanpaan-Hiekkila, E. Alhave, M. Olkinuora, and I. Plava Agranulocytosis during treatment with clozapine European Journal of Clinical Pharmacology 11 1977 193 198 (Pubitemid 8072136)
51. D.C. Javitt Glycine transport inhibitors and the treatment of schizophrenia Biological Psychiatry 63 2008 6 8 (Pubitemid 350234898)
52. D.C. Javitt Glycine transport inhibitors for the treatment of schizophrenia: symptom and disease modification Current Opinion in Drug Discovery & Development 12 2009 468 478
53. N.H. Jensen, T.I. Cremers, and F. Sotty Therapeutic potential of 5-HT2C receptor ligands The Scientific World Journal 10 2010 1870 1885
54. P.B. Jones, T.R.E. Barnes, L. Davies, G. Dunn, H. Lloyd, K.P. Hayhurst, R.M. Murray, A. Markwick, and S.W. Lewis Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1) Archives of General Psychiatry 63 2006 1079 1087 (Pubitemid 44498387)
55. J.M. Kane, G. Honigfeld, J. Singer, and H.Y. Meltzer Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine Archives of General Psychiatry 45 1988 789 796
56. J.T. Kantrowitz, A.K. Malhotra, B. Cornblatt, G. Silipo, A. Balla, R.F. Suckow, C. D'Souza, J. Saksa, S.W. Woods, and D.C. Javitt High dose d-serine in the treatment of schizophrenia Schizophrenia Research 121 2010 125 130
57. R.S.E. Keefe, R.M. Bilder, S.M. Davis, P.D. Harvey, B.W. Palmer, J.M. Gold, H.Y. Meltzer, M.F. Green, G. Capuano, T.S. Stroup, J.P. McEvoy, M.S. Swartz, R.A. Roscnheck, D.O. Perkins, C.E. Davis, J.K. Hsiao, and J.A. Lieberman Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial Archives of General Psychiatry 64 2007 633 647 (Pubitemid 46878665)
58. L.S. Kegeles, A. Abi-Dargham, W.G. Frankle, R. Gil, T.B. Cooper, M. Slifstein, D.R. Hwang, Y. Huang, S.N. Haber, and M. Laruelle Increased synaptic dopamine function in associative regions of the striatum in schizophrenia Archives of General Psychiatry 67 2010 231 239
59. K.S. Kendler, and M.C. Neale Endophenotype: a conceptual analysis Molecular Psychiatry 15 2010 8
60. J.S. Kim, H.H. Kornhuber, W. Schmid-Burgk, and B. Holzmuller Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia Neuroscience Letters 20 1980 379 382 (Pubitemid 11160082)
61. M.V. King, A.J. Sleight, M.L. Woolley, I.A. Topham, C.A. Marsden, and K.C.F. Fone 5-HT6 receptor antagonists reverse delay-dependent deficits in novel object discrimination by enhancing consolidation - an effect sensitive to NMDA receptor antagonism Neuropharmacology 47 2004 195 204 (Pubitemid 38824643)
62. B.J. Kinon, L. Zhang, J.E. Williams, O.O. Osuntokun, B.A. Millen, and S. Kollack-Walker LY2140023 monohydrate: an agonist at the MGlu2/3 receptor for the trearment of schizophrenia Schizophrenia Research 117 2010 379
63. I. Kola, and J. Landis Can the pharmaceutical industry reduce attrition rates? Nature Reviews Drug Discovery 3 2004 711 715 (Pubitemid 39173511)
64. H.H. Kornhuber Chemistry, physiology and neuropsychology of schizophrenia: towards an earlier diagnosis of schizophrenia Archiv fur Psychiatrie und Nervenkrankheiten 233 1983 415 422 (Pubitemid 14151081)
65. M.S. Kramer, B. Last, A. Getson, and S.A. Reines The effects of a selective D4 dopamine receptor antagonist (L- 745,870) in acutely psychotic inpatients with schizophrenia. D4 dopamine antagonist group [published erratum appears in Arch Gen Psychiatry 1997 Dec;54(12):1080] Archives of General Psychiatry 54 1997 567 572 (Pubitemid 27258555)
66. H.Y. Lane, Y.C. Chang, Y.C. Liu, C.C. Chiu, and G.E. Tsai Sarcosine or d-serine add-on treatment for acute exacerbation of schizophrenia - a randomized, double-blind, placebo-controlled study Archives of General Psychiatry 62 2005 1196 1204 (Pubitemid 41586919)
67. H.Y. Lane, C.H. Lin, Y.J. Huang, C.H. Liao, Y.C. Chang, and G.E. Tsai A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and d-serine add-on treatment for schizophrenia International Journal of Neuropsychopharmacology 13 2010 451 460
68. M. Laruelle, A. Abi-Dargham, C.H. van Dyck, R. Gil, C.D. D'Souza, J. Erdos, E. McCance, W. Rosenblatt, C. Fingado, S.S. Zoghbi, R.M. Baldwin, J.P. Seibyl, J.H. Krystal, D.S. Charney, and R.B. Innis Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects Proceedings of the National Academy of Sciences U S A 93 1996 9235 9240
69. J. Laskey, C. Klett, E. Caffey, J. Bennett, M. Rosenblum, and L. Hollister A comparison evaluation of chlorpromazine, chrloprothixene, fluphenazine, reserpine, thioridazine and ttriflupromazine Diseases of the Nervous System 23 1962 8
70. S. Leucht, K. Komossa, C. Rummel-Kluge, C. Corves, H. Hunger, F. Schmid, C. Asenjo Lobos, S. Schwarz, and J.M. Davis A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia American Journal of Psychiatry 166 2009 152 163
71. R. Leurs, R.A. Bakker, H. Timmerman, and I.J.P. de Esch The histamine H-3 receptor: from gene cloning to H-3 receptor drugs Nature Reviews Drug Discovery 4 2005 107 U118
72. J.C. Leveque, W. Macias, A. Rajadhyaksha, R.R. Carlson, A. Barczak, S. Kang, X.M. Li, J.T. Coyle, R.L. Huganir, S. Heckers, and C. Konradi Intracellular modulation of NMDA receptor function by antipsychotic drugs Journal of Neuroscience 20 2000 4011 4020 (Pubitemid 30365671)
73. J.A. Lieberman, T. Scott Stroup, J.P. McEvoy, M.S. Swartz, R.A. Rosenheck, D.O. Perkins, R.S.E. Keefe, S.M. Davis, C.E. Davis, B.D. Lebowitz, J. Severe, and J.K. Hsiao Effectiveness of antipsychotic drugs in patients with chronic schizophrenia New England Journal of Medicine 353 2005 1209 1223 (Pubitemid 41345943)
74. M. Liem-Moolenaar, R.W.M. Zoethout, P. De Boer, M. Schmidt, M.L. De Kam, A.F. Cohen, K.L. Franson, and J.M.A. Van Gerven The effects of a glycine reuptake inhibitor R231857 on the central nervous system and on scopolamine-induced impairments in cognitive and psychomotor function in healthy subjects Journal of Psychopharmacology 24 2010 1681 1687
75. X. Ligneau, L. Landais, D. Perrin, J. Piriou, M. Uquen, E. Denis, P. Robert, R. Parmentier, C. Anaclet, J.S. Lin, A. Burban, J.M. Arrang, and J.C. Schwartz Brain histamine and schizophrenia: potential therapeutic applications of H-3-receptor inverse agonists studied with BF2.649 Biochemical Pharmacology 73 2007 1215 1224 (Pubitemid 46420689)
76. E.D. Luby, B.D. Cohen, G. Rosenbaum, J.S. Gottlieb, and R. Kelley Study of a new schizophrenomimetic drug - sernyl Americam Medical Association Archives of Neurology and Psychiatry 81 1959 363 369
77. D.C. Mamo, S. Natesan, S. VanderSpek, and S. Kapur l-stepholidine: a D-1 agonist D-2 antagonist with an antipsychotic-like profile Schizophrenia Bulletin 31 2005 305
78. K.L. Marquis, S. Grauer, J. Brennan, M. Piesla, T.A. Comery, A. Sabb, G. Stack, L.A. Dawson, C.R. Ashby, H.Y. Meltzer, and S. Rosenzweig-Lipson WAY-163909, a novel selective, 5-HT2C receptor agonist, exhibits an atypical antipsychotic-like profile: behavioral, neurochemical and electrophysiological evidence Neuropsychopharmacology 29 2004 S172
79. K.L. Marquis, N. Ator, J. Dunlop, S. Ramamoorthy, C. Beyer, Q. Lin, J. Brennan, M. Piesla, C. Ashby, B. Harrison, R. Magolda, M.N. Pangalos, G. Stack, and S. Rosenzweig-Lipson Antipsychotic-like effects of SCA-136: a novel 5-HT2C receptor agonist Neuropsychopharmacology 30 2005 S251 S252
80. J.P. McEvoy, J.A. Lieberman, T.S. Stroup, S.M. Davis, H.Y. Meltzer, R.A. Rosenheck, M.S. Swartz, D.O. Perkins, R.S.E. Keefe, C.E. Davis, J. Severe, and J.K. Hsiao Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment American Journal of Psychiatry 163 2006 600 610 (Pubitemid 44464569)
81. A.D. Medhurst, A.R. Atkins, I.J. Beresford, K. Brackenborough, M.A. Briggs, A.R. Calver, J. Cilia, J.E. Cluderay, B. Crook, J.B. Davis, R.K. Davis, R.P. Davis, L.A. Dawson, A.G. Foley, J. Gartlon, M.I. Gonzalez, T. Heslop, W.D. Hirst, C. Jennings, D.N.C. Jones, L.P. Lacroix, A. Martyn, S. Ociepka, A. Ray, C.M. Regan, J.C. Roberts, J. Schogger, E. Southam, T.O. Stean, B.K. Trail, N. Upton, G. Wadsworth, J.A. Wald, T. White, J. Witherington, M.L. Woolley, A. Worby, and D.M. Wilson GSK189254, a novel H-3 receptor antagonist that binds to histamine H-3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models Journal of Pharmacology and Experimental Therapeutics 321 2007 1032 1045 (Pubitemid 46762709)
82. H.Y. Meltzer The role of serotonin in antipsychotic drug action Neuropsychopharmacology 21 1999 S106 S115
83. P. Michal, M. Lysikova, F.E.E. El, and S. Tucek Clozapine interaction with the M-2 and M-4 subtypes of muscarinic receptors European Journal of Pharmacology 376 1999 119 125 (Pubitemid 29320177)
84. F. Micheli, and C. Heidbreder Selective dopamine D3 receptor antagonists. A decade of progress: 1997-2007 Expert Opinion on Therapeutic Patents 18 2008 821 840
85. M.J. Millan N-methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives Psychopharmacology 179 2005 30 53 (Pubitemid 40576691)
86. M.J. Millan, A. Dekeyne, and A. Gobert Serotonin (5-HT)(2C) receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo Neuropharmacology 37 1998 953 955
87. M.J. Millan, C.M. La Cour, F. Novi, R. Maggio, V. Audinot, A. Newman-Tancredi, D. Cussac, V. Pasteau, J.A. Boutin, T. Dubuffet, and G. Lavielle S33138(N-[4-[2-[(3aS, 9bR)-8-cyano-1,3a, 4,9b-tetrahydro[1]- benzopyrano[3,4-c] pyrrol-2(3H)-yl)-ethyl]phenylacetamide), a preferential dopamine D-3 versus D-2 receptor antagonist and potential antipsychotic agent: I. Receptor-binding profile and functional actions at G-protein-coupled receptors Journal of Pharmacology and Experimental Therapeutics 324 2008 587 599 (Pubitemid 351185866)
88. H.J. Moller Do effectiveness ('real world') studies on antipsychotics tell us the real truth? European Archives of Psychiatry and Clinical Neuroscience 258 2008 257 270
89. National Institute of Mental, H Phenothiazine treatment in acute schizophrenics Archives of General Psychiatry 10 1964 246 261
90. A. Newman-Tancredi The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives Current Opinion in Investigational Drugs 11 2010 802 812
91. A. Olincy, and K.E. Stevens Treating schizophrenia symptoms with an α7 nicotinic agonist, from mice to men Biochemical Pharmacology 74 2007 1192 1201 (Pubitemid 47417932)
92. A. Olincy, J.G. Harris, L.L. Johnson, V. Pender, S. Kongs, D. Allensworth, J. Ellis, G.O. Zerbe, S. Leonard, K.E. Stevens, J.O. Stevens, L. Martin, L.E. Adler, F. Soti, W.R. Kem, and R. Freedman Proof-of-concept trial of an alpha 7 nicotinic agonist in schizophrenia Archives of General Psychiatry 63 2006 630 638 (Pubitemid 43848294)
93. S.T. Patil, L. Zhang, F. Martenyi, S.L. Lowe, K.A. Jackson, B.V. Andreev, A.S. Avedisova, L.M. Bardenstein, I.Y. Gurovich, M.A. Morozova, S.N. Mosolov, N.G. Neznanov, A.M. Reznik, A.B. Smulevich, V.A. Tochilov, B.G. Johnson, J.A. Monn, and D.D. Schoepp Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial Nature Medicine 13 2007 1102 1107 (Pubitemid 47517511)
94. O. Perl, T. Ilani, R.D. Strous, R. Lapidus, and S. Fuchs The αλπηα7 nicotinic acetylcholine receptor in schizophrenia: decreased mRNA levels in peripheral blood lymphocytes FASEB Journal 17 2003 3
95. C. Plisson, R.N. Gunn, V.J. Cunningham, D. Bender, C.A. Salinas, A.D. Medhurst, J.C. Roberts, M. Laruelle, and A.D. Gee 11C-GSK189254: a selective radioligand for in vivo central nervous system imaging of histamine H3 receptors by PET Journal of Nuclear Medicine 50 2009 2064 2072
96. B. Pouzet, M. Didriksen, and J. Arnt Effects of the 5-HT6 receptor antagonist, SB-271046, in animal models for schizophrenia Pharmacology Biochemistry and Behavior 71 2002 635 643 (Pubitemid 34219214)
97. E.P.M. Prinssen, F.C. Colpaert, and W. Koek 5-HT1A receptor activation and anti-cataleptic effects: high-efficacy agonists maximally inhibit haloperidol-induced catalepsy European Journal of Pharmacology 453 2002 217 221 (Pubitemid 35223513)
98. G.P. Reynolds, and S.L. Kirk Metabolic side effects of antipsychotic drug treatment - pharmacological mechanisms Pharmacology and Therapeutics 125 2010 169 179
99. J.S. Rodefer, E.R. Murphy, and M.G. Baxter PDE10A inhibition reverses subchronic PCP-induced deficits in attentional set-shifting in rats European Journal of Neuroscience 21 2005 1070 1076 (Pubitemid 40461058)
100. 6 receptor antagonist: comparison among antipsychotics Neuropsychopharmacology 33 2008 2657 2666
101. D.C. Rogers, and J.J. Hagan 5-HT6 receptor antagonists enhance retention of a water maze task in the rat Psychopharmacology 158 2001 114 119 (Pubitemid 33020829)
102. B.L. Roth, S.C. Craigo, M.S. Choudhary, A. Uluer, F.J. Monsma Jr.; Y. Shen, H.Y. Meltzer, and D.R. Sibley Binding of typical and atypical antipsychotic agents to 5- hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors Journal of Pharmacology and Experimental Therapeutics 268 1994 1403 1410 (Pubitemid 24100360)
103. C. Rummel-Kluge, K. Komossa, S. Schwarz, H. Hunger, F. Schmid, W. Kissling, J.M. Davis, and S. Leucht Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons Schizophrenia Bulletin 2010
104. H. Sano, Y. Nagai, T. Miyakawa, R. Shigemoto, and M. Yokoi Increased social interaction in mice deficient of the striatal medium spiny neuron-specific phosphodiesterase 10A2 Journal of Neurochemistry 105 2008 546 556 (Pubitemid 351490018)
105. C.J. Schmidt, D.S. Chapin, J. Cianfrogna, M.L. Corman, M. Hajos, J.F. Harms, W.E. Hoffman, L.A. Lebel, S.A. McCarthy, F.R. Nelson, C. Proulx-LaFrance, M.J. Majchrzak, A.D. Ramirez, K. Schmidt, P.A. Seymour, J.A. Siuciak, F.D. Tingley Iii, R.D. Williams, P.R. Verhoest, and F.S. Menniti Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia Journal of Pharmacology and Experimental Therapeutics 325 2008 681 690 (Pubitemid 351574819)
106. P. Seeman, T. Tallerico, R. Corbett, T.H.H. Van, and R.K. Kamboj Role of dopamine D2, D4 and serotonin(2A) receptors in antipsychotic and anticataleptic action Journal of Psychopharmacology 11 1997 15 17 (Pubitemid 27146029)
107. M. Shahid, G.B. Walker, S.H. Zorn, and E.H.F. Wong Asenapine: a novel psychopharmacologic agent with a unique human receptor signature Journal of Psychopharmacology 23 2009 65 73
108. W.W. Shen A history of antipsychotic drug development Comprehensive Psychiatry 40 1999 407 414
109. R. Shigemoto, A. Kinoshita, E. Wada, S. Nomura, H. Ohishi, M. Takada, P.J. Flor, A. Neki, T. Abe, S. Nakanishi, and N. Mizuno Differential presynaptic localization of metabotropic glutamate receptor subtypes in the rat hippocampus Journal of Neuroscience 17 1997 7503 7522 (Pubitemid 27413281)
110. J.A. Siuciak, S.A. McCarthy, D.S. Chapin, R.A. Fujiwara, L.C. James, R.D. Williams, J.L. Stock, J.D. McNeish, C.A. Strick, F.S. Menniti, and C.J. Schmidt Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal function Neuropharmacology 51 2006 374 385 (Pubitemid 44061880)
111. J.A. Siuciak, D.S. Chapin, S.A. McCarthy, V. Guanowsky, J. Brown, P. Chiang, R. Marala, T. Patterson, P.A. Seymour, A. Swick, and P.A. Iredale CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity Neuropharmacology 52 2007 279 290 (Pubitemid 46123348)
112. J.A. Siuciak, D.S. Chapin, S.A. McCarthy, A.N. Martin, J.F. Harms, C.B. Fox, T.A. Chappie, J.M. Humphrey, C.A. Proulx, P.R. Verhoest, and C.J. Schmidt Novel potent and selective PDE10A inhibitors show activity in animal models of psychosis and anxiety Schizophrenia Bulletin 33 2007 479
113. S.M. Smith, J.M. Uslaner, and P.H. Hutson The therapeutic potential of D-amino acid oxidase (DAAO) inhibitors Open Medicinal Chemistry Journal 4 2010 3 9
114. E. Southam, J. Cilia, J.E. Gartlon, M.L. Woolley, L.P. Lacroix, C.A. Jennings, J.E. Cluderay, C. Reavill, C. Rourke, D.M. Wilson, L.A. Dawson, A.D. Medhurst, and D.N.C. Jones Preclinical investigations into the antipsychotic potential of the novel histamine H-3 receptor antagonist GSK207040 Psychopharmacology 201 2009 483 494
115. A.J. Steck Milestones in the development of neurology and psychiatry in Europe Schweizer Archiv fur Neurologie und Psychiatrie 161 2010 85 89
116. S. Tang, M. Verdurand, B. Joseph, L. Lemoine, A. Daoust, T. Billard, G. Fournet, D. Le Bars, and L. Zimmer Synthesis and biological evaluation in rat and cat of [18F]12ST05 as a potential 5-HT6 PET radioligand Nuclear Medicine and Biology 34 2007 995 1002 (Pubitemid 350081075)
117. I. Tarricone, B. Ferrari Gozzi, A. Serretti, D. Grieco, and D. Berardi Weight gain in antipsychotic-naive patients: a review and meta-analysis Psychological Medicine 40 2010 187 200
118. J. Toyohara, and K. Hashimoto α7 nicotinic receptor agonists: potential therapeutic drugs for treatment of cognitive impairments in schizophrenia and Alzheimer's disease Open Medicinal Chemistry Journal 4 2010 37 56
119. J. Toyohara, K. Ishiwata, M. Sakata, J. Wu, S. Nishiyama, H. Tsukada, and K. Hashimoto In vivo evaluation of carbon-11-labelled non-sarcosine-based glycine transporter 1 inhibitors in mice and conscious monkeys Nuclear Medicine and Biology 2011
120. G.E. Tsai, and P.Y. Lin Strategies to enhance N-methyl-d-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis Current Pharmaceutical Design 16 2010 522 537
121. E.H.F. Wong, F. Yocca, M.A. Smith, and C.M. Lee Challenges and opportunities for drug discovery in psychiatric disorders: the drug hunters' perspective International Journal of Neuropsychopharmacology 13 2010 1269 1284
122. C.R. Yang, and K.A. Svensson Allosteric modulation of NMDA receptor via elevation of brain glycine and d-serine: the therapeutic potentials for schizophrenia Pharmacology and Therapeutics 120 2008 317 332
123. A. Yasuhara, and S. Chaki Metabotropic glutamate receptors: potential drug targets for psychiatric disorders Open Medicinal Chemistry Journal 4 2010 20 36
124. K. Yoshida, T. Sugita, H. Higuchi, and Y. Hishikawa Effect of tandospirone on tardive dyskinesia and parkinsonian symptoms European Psychiatry 13 1998 421 422
125. F. Zafra, J. Gomeza, L. Olivares, C. Aragon, and C. Gimenez Regional distribution and developmental variation of the glycine transporters GLYT1 and GLYT2 in the rat CNS European Journal of Neuroscience 7 1995 1342 1352